Limits...
Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.

Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, Han H, Liu Z, Li X, Tang A, Gui Y, Cai Z, Zhou F - BMC Cancer (2011)

Bottom Line: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001).We found that decreased expression of DUSP-9 is associated with poor prognosis in ccRCC.DUSP-9 may represent a novel and useful prognostic marker for ccRCC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, PR China.

ABSTRACT

Background: The molecular mechanisms involved in the development and progression of clear cell renal cell carcinomas (ccRCCs) are poorly understood. The objective of this study was to analyze the expression of dual-specificity phosphatase 9 (DUSP-9) and determine its clinical significance in human ccRCCs.

Methods: The expression of DUSP-9 mRNA was determined in 46 paired samples of ccRCCs and adjacent normal tissues by using real-time qPCR. The expression of the DUSP-9 was determined in 211 samples of ccRCCs and 107 paired samples of adjacent normal tissues by immunohistochemical analysis. Statistical analysis was performed to define the relationship between the expression of DUSP-9 and the clinical features of ccRCC.

Results: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). An immunohistochemical analysis of 107 paired tissue specimens showed that the DUSP-9 expression was lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). Moreover, there was a significant correlation between the DUSP-9 expression in ccRCCs and gender (p = 0.031), tumor size (p = 0.001), pathologic stage (p = 0.001), Fuhrman grade (p = 0.002), T stage (p = 0.001), N classification (p = 0.012), metastasis (p = 0.005), and recurrence (p < 0.001). Patients with lower DUSP-9 expression had shorter overall survival time than those with higher DUSP-9 expression (p < 0.001). Multivariate analysis indicated that low expression of the DUSP-9 was an independent predictor for poor survival of ccRCC patients.

Conclusion: To our knowledge, this is the first study that determines the relationship between DUSP-9 expression and prognosis in ccRCC. We found that decreased expression of DUSP-9 is associated with poor prognosis in ccRCC. DUSP-9 may represent a novel and useful prognostic marker for ccRCC.

Show MeSH

Related in: MedlinePlus

Survival analysis of primary ccRCC patients (n = 211). (A) Overall survival. Kaplan-Meier survival analysis of primary ccRCC patients (n = 211) after surgical resection with low DUSP-9 expression (n = 117) and high DUSP-9 expression (n = 94). The survival rate for patients in the DUSP-9 low group was significantly lower than that for patients in the DUSP-9 positive group (log-rank test, p<0.001). (B) Pathological stage I-II; (C) Pathological stage III; (D) Pathological stage IV. Statistical analysis of the difference between DUSP-9 high-expressing and low-expressing tumors was compared in the I-II( B), III(C) and IV (D) patient subgroups. The longest follow-up time is 124 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198720&req=5

Figure 4: Survival analysis of primary ccRCC patients (n = 211). (A) Overall survival. Kaplan-Meier survival analysis of primary ccRCC patients (n = 211) after surgical resection with low DUSP-9 expression (n = 117) and high DUSP-9 expression (n = 94). The survival rate for patients in the DUSP-9 low group was significantly lower than that for patients in the DUSP-9 positive group (log-rank test, p<0.001). (B) Pathological stage I-II; (C) Pathological stage III; (D) Pathological stage IV. Statistical analysis of the difference between DUSP-9 high-expressing and low-expressing tumors was compared in the I-II( B), III(C) and IV (D) patient subgroups. The longest follow-up time is 124 months.

Mentions: Kaplan-Meier analysis and the log-rank test were used to calculate the effect of the DUSP-9 expression on survival. The 5-year survival in the group of patients with high DUSP-9 expression was 97%, but it was 62.1% in the group of patients with low DUSP-9 expression (Figure 4A). The log-rank test showed that survival rates were significantly different between these 2 groups (p < 0.001). Furthermore, the relationship of DUSP-9 expression with prognosis was determined in 211 patients, which were divided into 3 subgroups depending on the pathologic stage. Patients with tumors exhibiting high DUSP-9 expression had significantly longer overall survival than those with low expression of DUSP-9 either in the stage I plus II subgroup (n = 151; log-rank, p = 0.023; Figure 4B), the stage III sub group (n = 31; log-rank, p = 0.036; Figure 4C), or the stage IV subgroup (n = 29; log-rank, p = 0.038; Figure 4D). Patients with tumors high DUSP-9 expression had significantly longer overall survival than those with low expression of DUSP-9 either in the Fuhrman grade I subgroup(n = 39; log-rank, p = 0.005; Additional file 1 Figure S1A), II subgroup (n = 123; log-rank, p < 0.0001; Additional file 1 Figure S1B), the stage III sub group (n = 34; log-rank, p < 0.001; Additional file 1 Figure S1C), or the stage IV subgroup (n = 15; log-rank, p = 0.019; Additional file 1 Figure S1D).


Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.

Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, Han H, Liu Z, Li X, Tang A, Gui Y, Cai Z, Zhou F - BMC Cancer (2011)

Survival analysis of primary ccRCC patients (n = 211). (A) Overall survival. Kaplan-Meier survival analysis of primary ccRCC patients (n = 211) after surgical resection with low DUSP-9 expression (n = 117) and high DUSP-9 expression (n = 94). The survival rate for patients in the DUSP-9 low group was significantly lower than that for patients in the DUSP-9 positive group (log-rank test, p<0.001). (B) Pathological stage I-II; (C) Pathological stage III; (D) Pathological stage IV. Statistical analysis of the difference between DUSP-9 high-expressing and low-expressing tumors was compared in the I-II( B), III(C) and IV (D) patient subgroups. The longest follow-up time is 124 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198720&req=5

Figure 4: Survival analysis of primary ccRCC patients (n = 211). (A) Overall survival. Kaplan-Meier survival analysis of primary ccRCC patients (n = 211) after surgical resection with low DUSP-9 expression (n = 117) and high DUSP-9 expression (n = 94). The survival rate for patients in the DUSP-9 low group was significantly lower than that for patients in the DUSP-9 positive group (log-rank test, p<0.001). (B) Pathological stage I-II; (C) Pathological stage III; (D) Pathological stage IV. Statistical analysis of the difference between DUSP-9 high-expressing and low-expressing tumors was compared in the I-II( B), III(C) and IV (D) patient subgroups. The longest follow-up time is 124 months.
Mentions: Kaplan-Meier analysis and the log-rank test were used to calculate the effect of the DUSP-9 expression on survival. The 5-year survival in the group of patients with high DUSP-9 expression was 97%, but it was 62.1% in the group of patients with low DUSP-9 expression (Figure 4A). The log-rank test showed that survival rates were significantly different between these 2 groups (p < 0.001). Furthermore, the relationship of DUSP-9 expression with prognosis was determined in 211 patients, which were divided into 3 subgroups depending on the pathologic stage. Patients with tumors exhibiting high DUSP-9 expression had significantly longer overall survival than those with low expression of DUSP-9 either in the stage I plus II subgroup (n = 151; log-rank, p = 0.023; Figure 4B), the stage III sub group (n = 31; log-rank, p = 0.036; Figure 4C), or the stage IV subgroup (n = 29; log-rank, p = 0.038; Figure 4D). Patients with tumors high DUSP-9 expression had significantly longer overall survival than those with low expression of DUSP-9 either in the Fuhrman grade I subgroup(n = 39; log-rank, p = 0.005; Additional file 1 Figure S1A), II subgroup (n = 123; log-rank, p < 0.0001; Additional file 1 Figure S1B), the stage III sub group (n = 34; log-rank, p < 0.001; Additional file 1 Figure S1C), or the stage IV subgroup (n = 15; log-rank, p = 0.019; Additional file 1 Figure S1D).

Bottom Line: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001).We found that decreased expression of DUSP-9 is associated with poor prognosis in ccRCC.DUSP-9 may represent a novel and useful prognostic marker for ccRCC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, PR China.

ABSTRACT

Background: The molecular mechanisms involved in the development and progression of clear cell renal cell carcinomas (ccRCCs) are poorly understood. The objective of this study was to analyze the expression of dual-specificity phosphatase 9 (DUSP-9) and determine its clinical significance in human ccRCCs.

Methods: The expression of DUSP-9 mRNA was determined in 46 paired samples of ccRCCs and adjacent normal tissues by using real-time qPCR. The expression of the DUSP-9 was determined in 211 samples of ccRCCs and 107 paired samples of adjacent normal tissues by immunohistochemical analysis. Statistical analysis was performed to define the relationship between the expression of DUSP-9 and the clinical features of ccRCC.

Results: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). An immunohistochemical analysis of 107 paired tissue specimens showed that the DUSP-9 expression was lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). Moreover, there was a significant correlation between the DUSP-9 expression in ccRCCs and gender (p = 0.031), tumor size (p = 0.001), pathologic stage (p = 0.001), Fuhrman grade (p = 0.002), T stage (p = 0.001), N classification (p = 0.012), metastasis (p = 0.005), and recurrence (p < 0.001). Patients with lower DUSP-9 expression had shorter overall survival time than those with higher DUSP-9 expression (p < 0.001). Multivariate analysis indicated that low expression of the DUSP-9 was an independent predictor for poor survival of ccRCC patients.

Conclusion: To our knowledge, this is the first study that determines the relationship between DUSP-9 expression and prognosis in ccRCC. We found that decreased expression of DUSP-9 is associated with poor prognosis in ccRCC. DUSP-9 may represent a novel and useful prognostic marker for ccRCC.

Show MeSH
Related in: MedlinePlus